Parasitic-Industries Analysis and Arguments for a Living Wage for Women in the Early Twentieth-Century United States

This paper examines arguments by activists and economists surrounding attempts to establish minimum wages for women in the United States in the Progressive Era. In particular, the paper focuses on analyses based on Beatrice and SidneyWebbs' argument that industries paying less than a living wage were "parasitic" on the society, a net drain on macro-efficiency. This analysis, widely accepted among economists of the time, viewed women as particularly vulnerable workers facing labor markets that were institutionally constructed and predatory. Unequal gender roles, employer power, and the absence of collective bargaining could all result in wages that were socially unacceptable as well as economically nonoptimal. These debates offer insights for modern feminist wage theories, and for current living wage campaigns.     

The Evolution and Devolution of Bank Regulation in the United States

Development economics is understood as a postwar phenomenon without antecedents. Yet, Veblen's contribution to development economics was once widely disseminated and acknowledged. Veblen's evolutionary economics centered on historically relative and limited truths applicable to specific cultures. Veblen's growth theory is a theory of economic development: quantitative accumulation is significant because it engenders qualitative change. Veblen's analysis of the harnessing of the economic potential centers on the ability of a society to successfully introduce scientific and technological advances, giving rise to increasing returns as the surplus is invested in industrial activities. Veblen presented oblique comments and startling insights in a non-empirical manner.     

美欧煤炭期货市场发展研究

文章以美欧上市煤炭期货前后背景为出发点,分析美国和欧洲上市煤炭期货前后的经济环境、煤炭市场供需情况以及上市后的市场运行情况等,并对美欧煤炭期货市场进行对比分析,引出现代期货市场已经具有为生产者、经营者、消费者甚至投机者在内的一种市场导向功能,特别是生产导向功能方面表现最为明显。     

美国区域产业调节法律制度构建与启示

文章对美国区域产业调节法律制度的历史变迁及主要内容进行了考察,分析了美国构建区域产业调节法律制度以促进区域经济协调的主要措施与成功经验。通过历史分析、规范分析等方法,研究了美国通过设立综合性区域产业调节机构,创立促进西部地区产业结构升级机制,建立倾斜支持区域农业发展机制,健全区域产业调节工具协调机制以构建区域产业调节法律制度,规范政府区域产业调节行为,促进市场机制和政府调节机制协同运作的基本做法。研究表明,美国的相关成功经验对我国区域产业调节法律制度合理处理市场调节与政府调节机制之间的关系,建立综合性的区域调节机构,明确区域产业调节作用的重点,建立完整的区域产业调节制度体系等方面具有重要的启示与借鉴作用。     

The economic burden of brain metastasis among lung cancer patients in the United States

Objective:

Brain metastases among lung cancer patients can impair cognitive and functional ability, complicate care, and reduce survival. This study focuses on the economic burden of brain metastasis in lung cancer—direct healthcare costs to payers and indirect costs to patients, payers, and employers—in the US.

Methods:

Retrospective study using claims data from over 60 self-insured Fortune 500 companies across all US census regions (January 1999–March 2013). Adult, non-elderly lung cancer patients with brain metastasis were evaluated over two study periods: (1) pre-diagnosis (≤30 days prior to first observed lung cancer diagnosis to ≤30 days prior to first-observed brain metastasis diagnosis) and (2) post-diagnosis (≤30 days prior to first observed brain metastasis diagnosis to end of continuous eligibility or observation).

Outcome measures:

Healthcare costs to payers and resource utilization, salary loss to patients, disability payouts for payers, and productivity loss to employers.

Results:

A total of 132 patients were followed for a median of 8.4 and 6.6 months in the pre- and post-diagnosis periods, respectively. At diagnosis of brain metastasis, 21.2% of patients were on leave of absence and 6.1% on long-term disability leave. Substantial differences were observed in the pre- vs post-diagnosis periods. Specifically, patients incurred much greater healthcare utilization in the post-diagnosis period, resulting in $25,579 higher medical costs per-patient-per-6-months (PPP6M). During this period, patients missed significantly more work days, generating an incremental burden of $2853 PPP6M in salary loss for patients, $2557 PPP6M in disability payments for payers, and $4570 PPP6M in productivity loss for employers.

Limitations:

Type of primary lung cancer and extent of brain metastasis could not be assessed in the data. The analysis was also limited to patients with comprehensive disability coverage.

Conclusions:

Development of brain metastasis among lung cancer patients is associated with a substantial economic burden to payers, patients, and employers.     

The economic burden of common adverse events associated with metastatic colorectal cancer treatment in the United States

Aims: Adverse events (AEs) associated with treatments for metastatic colorectal cancer (mCRC) may compromise the course of treatment, impact quality-of-life, and increase healthcare resource utilization. This study assessed the direct healthcare costs of common AEs among mCRC patients in the US.

Methods: Adult mCRC patients treated with chemotherapy or targeted therapies were identified from administrative claims databases (2009–2014). Up to the first three mCRC treatment episodes per patient were considered and categorized as with or without the AE system/organ category during the episode. Total healthcare costs (2014 USD) were measured by treatment episode and reported on a monthly basis. Treatment episodes with the AE category were matched by treatment type and line of treatment to those without the AE category. Adjusted total cost differences were estimated by comparing costs during treatment episodes with vs without the AE category using multivariate regression models; p-values were estimated with bootstrap.

Results: A total of 4158 patients with ≥1 mCRC treatment episode were included (mean age?=?59 years; 58% male; 60% with liver and 14% with lung metastases; 2,261 [54%] with a second and 1,115 [27%] with a third episode). On average, two treatment episodes were observed per patient with an average length of 166 days per episode. Adjusted monthly total cost difference by AE category included hematologic ($1,480), respiratory ($1,253), endocrine/metabolic ($1,213), central nervous system (CNS; $1,136), and cardiovascular ($1,036; all p?Limitations: Claims do not include information on the cause of AEs, and potentially less severe AEs may not have been reported by the physician when billing the medical service. This study aimed to assess the association between costs and AEs and not the causation of AEs by treatment.

Conclusions: The most costly AEs among mCRC patients were hematologic, followed by respiratory, endocrine/metabolic, CNS, and cardiovascular.